Inclusion Criteria:  Confirmed HCC pathological or non-invasive assessment according to American Association for the Study of Liver Diseases (AASLD) criteria ECOG performance status 0 or 1 Patients who received Atezolizumab and Bevacizumab combination therapy as first-line systemic treatment for unresectable HCC Barcelona Clinic Liver Cancer (BCLC) stage B or C Child-Pugh class A Measurable lesion Adequate hematologic and organ function  Exclusion Criteria:  History of autoimmune disease Concomitant anticoagulation at therapeutic doses. Low dose aspirin for cardio protection is permitted.